The urine and plasma of epileptic patients receiving therapeutic doses of valproic acid (2-propylpentanoic acid) was found to contain five doubly unsaturated metabolites of valproic acid, which were identified äs their trimethylsilyl derivatives by GC/MS. A series of reference substances was synthesized but only two of them were identical with native metabolites: 2(2-propenyl)-4-pentenoic acid (= 4.4'-diene) and E-2-propyl-2.4-pentadienoic acid (E-2.4-diene). The mass-spectra of the five native metabolites are given. Preliminary quantitative data obtained from four groups of patients indicate increased formation of doubly unsaturated metabolites when valproic acid-induced side-effects are present, and in cases of fatal hepatic failure. The 4.4'-diene has hitherto been found only in fatal cases with hepatic injury. Quantitative data are presented äs % of the sum of valproic acid plus all its detected metabolites. 
Introduction
Valproic acid (2-propyl-pentaiioic acid) is a widely used antiepileptic einig extremely effective against absence and generalized toiuc-clonic seizures {!). It was commonly believed to be relatively free from adverse side-effects. During recent years, however, it has been incriminated äs the cause of severe, and in some instances fatal hepatic injuries (2) . Throughout the world, a total of 68 fatal cases have been recognized (3) . Early calculations revealed frequencies of 1:10000-1:20000 (4) and 1:50000 (5) . The pathogenesis of this fatal hepatic failure is not understood and the first case in which valproic acid metabolism could be studied was published by Kochen et al. (6) . The prominent feature in this patient was the abnormally increased formation of mono-and di-unsaturated metabolites of vaiproic acid. Therefore it seems necessary to further investigate this new group of doubly unsaturated metabolites, which we reported earlier (7) .
There are substantial problems in the synthesis of doubly unsaturated derivatives of vaiproic acid, because the introduction of two double bonds results in 14 different stereoisomers. Moreover, if carbon 2 in vaiproic acid becomes chiral then an additional 4 enantiomers must be taken into consideration: Both stereoisomers of the 3.4'-diene form enantiomers (D-and L-2(2-propenyl)-3-rmw-pentenoic acid and £>-and L-2(2-propenyl)-3-cw-pentenoic acid). In the case of the 3.3'-diene only 2(l-ira/2,s-propenyl)-3-c/s-pentenoic acid may be expected to form enantiomers.
In the present work, we report the detection of a total of five doubly unsaturated metabolites of vaiproic acid in patients ori vaiproic acid therapy. Preliminary quantitative data indicating the possible pathological importance of this new group of metabolites are also presented.
Methods and Materials

Vaiproic acid derivatives
The syntheses of doubly unsaturated vaiproic acid derivatives have been described by Klemens (8) .
All these compounds have not been described in literature except the 4.4'-diene (9, 10).
2(2-Propenyl)-4-pentenoic acid (4.4'-diene) was obtained by malonic ester synthesis using allylbromide, followed by saponification and decarboxylation.
2(2-Propenyl)-3-pentenoic acid (3.4'-diene): Knoevenagel-reaction of propionaldehyde and diethylmalonate, alkylation of the propylidenediethylmalonate with l-bromopropene-2, saponification and decarboxylation.
2(2-Propenyl)-2-pentenoic acid (2.4'-diene): acylation of diethylmalonate with propionylchloride, alkylation with allylbromide, reduction by NaBH4, decarboxylation, dehydration and saponification.
2-Propyl-2.4-pentadienoic acid (2.4-diene) was obtained by a Wittig reaction with 2-bromoethylpentanoate and acrolein.
2(l-Propenyl)-2-pentenoic acid (2.3'-diene): nucleophilic acylation of 1-bromopropane with umgepoltem crotonaldehyde followed by saponification.
Mass-spectra of the synthetic diene compounds
The synthetic products were purified by common methods. The trimethylsilylesters of the acids were analysed by GC/MS.
Determination of vaiproic acid metabolites by GC/MS
Sample preparation
50-200 μΐ of the sample (urine, plasma etc.) wefe added to 200 μ! of 0.5 mol/1 NaH 2 PO 4 buffer pH 5.0 containing 3 internal Standards (l μ § each of di-n-butylacetic acid, phenylbutyric acid and Ci9-alkane) and 20 μΐ glucuronidase/arylsulphatase (Serva, Heidelberg). After incubation of the mixture for 3 h at 37 °C the metabolites were extracted with ethyl acetate (3 times; 0.5 ml). The volume of the combined organic phases was reduced to about 20 μΐ (not to dryness!) under a stream of dry nitrogen. The acids were silylated with 10 μΐ Ν^6 ide (MSTFA, Machery & Nagel, D ren). 
Results
Synthetic diene compounds
GC/MS investigations demonstrated that the syrithesized products consisted of mixtures of isomers, which we have numbered /l, /2, etc. according to their increasing retention time. The isomers were not isolated and the stereo-chemical str cture remains unknown. Table l presents the mass-ions and their intensity in % base-peak. The most intensive massion above m/z 100 was selected Ιοί the base-peak; the fragments below m/z 90 were considered to be of minor importance, and were therefore ignored. In investigating new syntheses for diene compounds without a terminal double bond, we obtained a series of doubly unsaturated vaiproic acid derivatives which were characterized by GC/MS. Three of these (diene-S5, diene-S6, and diene-S7) are also listed in tablel.
Native diene metabolites
Synthetic hydroxylated vaiproic acid derivatives (hydroxylated in position 5, 4, 3 and 2) were added to control samples of urine and plasma, and the samples prepared for GC-analysis s described in inethods. Mass-fragmentographic analysis of hydroxylated vaiproic acid derivatives did not generate detectable unsaturated derivatives, i.e. dehydration does not occur under the conditions used.
As an example figure l presents the mass-fragmentographic chromatogram of a urine sample from an epileptic and extremely dystrophib patient treated Tab. l. Synthetic diene compounds of valproic acid and the EI mass^spectra of their trimethylsilyl derivatives. The most intense mass-ion above m/z 100 was taken äs base-peak (100%). Mass-ions below m/z 90 were abandoned. For further details of dienes S5, S6 and S7 see text.
Compound m/z (% base-peak)
with valproic acid. The usual mono-ene metabolites 2-propyl-3-pentenoic acid (3-ene) and 2-propyl-2-pentenoic acid (Z-and E-2-ene) (see arrow 2, 3 a and 3b), the oxidized metabolites (see arrow [8] [9] [10] [11] [12] , and three doubly unsaturated metabolites E-2-propyl-2.4.-pentadienoic acid (== E-2.4-diene, diene/l), diene/2, and diene/3 (see arrow [4] [5] [6] are all clearly demonstrated. Due to their low concentration it is usually impossible to detect them on the basis of the total ion current (TIC) alone, and especially diene/3 is ofteri hidden in the overlapping urea peak. Removal of urea by urease before extractiön remarkably facilitates the detection of diene/3. Mass-spectra of the diene metabolites were obtained from urine samples containing elevated amounts of the compounds concerned. The typical mass-fragmentographic iöns of the trimethylsilyl derivatives are the molecular ion m/z 212 and the M -15 mass m/z 197.
The mass spectfum of diene/l trimethylisilyi derivative (arrow 4 in fig. 1 ) is given in figure 2a and agrees well with that of the second isomer from the synthesis of 2-propyl-2.4-pentadienoic acid trimethylsilyl derivative (see fig. 2b ). The retention time of the native product is identical with that of the synthetic isomer characterized by the higher retention time (compare fig. 8 ). The M -15 mass ion of the native product was determined at m/z 197.0945 (theoretical value 197.0998). In view of the higher retention time of this isomer we assume that it has the following structure: E-2-propyl-2.4-pentadienoic acid trimethylsilyl derivative
The Irans position of the carboxylic and the ethylene group may also be derived from the stereoselective course of the synthesis (11). Valproic acid metabolites: 1) 2-propyl-4-pentenoic acid (4-ene), 2) 2-propyl-3-pentenoic acid (3-ene, sum of eis and trans), 3a and 3b) 2-propyl-2-pentenoic acid ((Z)2-ene and (E)2-ene),
diene/4, 8a and 8b) diastereomers of 2-propyl-4-hydroxy-pentanoic acid, 9) both diastereomers of 2-propyl-3-hydroxy-pentanoic acid, lOa and lOb) 2-propyl-3-hydroxy-2-pentenoic acid (3-ketoenol), 11) 2-propyl-5-hydroxy-pentanoic acid, 12) 2-propyIglutaric acid, 13) urea and other constituents. The mass-spectrum of diene/2 trimethylsilyl derivative (see arrow 5 in fig. 1 ) is given in figure 3 and is likewise characterized by the base^peak of m/z 122 s in E-2-propyl-2.4-pentadienoic acid trimethylsilyl derivative (= diene/l). Exactly defined reference compounds are not available for either diene/2 or the diene metabolites discussed in the following. As figure 8 indicates all defined synthetic diene com- pounds have shorter retention times. Only the synthetic products, diene-S5, diene-S6, and diene-S7 were found in small amounts s by-products in the synthesis of the 2.3'-diene and 3.3'-diene. Their mass-spectrometric data indicating a diene structure are therefore also listed in table 1. The positions of the two double bonds in these three unsaturated products were not elucidated.
In spite of the identical retention time of diene/2 and the synthetic product diene-S5 their mass-spectra differ with respect to the relative intensities of the typical mass-ions.
The mass-spectrum of diene/3 trimethylsilyl derivative ( fig. 4) is also in accordance with the presence of a doubly unsaturated metabolite s confirmed by high-resolution of the molecular ion (found m/z 212.1195, theoretical value 212.1232).
The following two doubly unsaturated metabolites were detected and identified in fatal cases (6, 12) , where s they are unknown in patients without complications. Identification of 2(2-propenyl)-4-pentenoic acid (4.4'-diene) was possible only because the samples of the patient concerned (6) contained a veiy low concentration of valproic acid. As demonstrated in figure 5 , the trimethylsilyl derivatives of the synthetic 4.4'-diene> 4-ene and valproic acid are eluted very close together under the gas Chromatographie conditions used, so that in the presence of an excess of valproic acid it is difficult to detect these two metabolites. The mass-spectrum of the native 4.4'-diene trimethylsilyl derivative is given in figure  6 and agrees well with that of the synthetic product. The relative intensity of m/z 122 amounts only to about 15% and the molecular ion m/z 212 ist not higher than 10% of the base-peak m/z 197, whose exact mass was determined at 197.1092 (theoretical value 197.0998).
The 4.4'-diene is not present in the sample shown in figure l, but the 4-ene (arrow 1) is present in inore than trace amounts. This metabolite is not normally detectable in urine or plasma, and its existence was confirmed by the characteristic mass-ions m/z 172 and 185 and by the addition of the authentic reference compound. The mass-spectrum of the 4-ene has been published in I.e. (6).
The last of the five diene metabolites has the highest retention time and is termed diene/4. As in the case of diene/3, it may be overlapped by urea. The molecular ion was determined at m/z 212.1300. The typical mass-ions indicate again a doubly unsaturated metabolite, although an authentic reference substance is still lacking (mass-spectrum fig. 7 ). In figure l traces of diene/4 were also detected by recording m/z 122. '' A comparison of the retention indices of both the synthetic and the native diene compounds is given in figure 8 . The synthetic products, diene-S5, diene-S6 and diene-S7 are not defined in respect to the position of the two double bonds and they are listed only on the basis of their increasing retention times, which are in the same order s those of the native diene-metabolites, diene/2, diene/3, and diene/4. For analytical purposes the ex ct relative retention times of the trimethylsilyl derivatives of valproic acid, the five diene metabolites, and the mono-ene metabolites are summarized in table 2. The gas Chromatographie peaks are more or less contaminated by other urinary acidic constituents which, depending on their Concentration, may completely overlap these valproic acid metabolites. The commonly found contamination products are also listed in table 2. 
Concentration of the diene metabolites in patients on valproic acid therapy
Preliminary quantitative results for diene metabolites found in four groups of patients (adults without side-effects, children with reversible side-effects such s vomiting, drowsiness, anorexia etc, one fatal case with hepatic failure (6), and children without complications in therapy) are given in table 3 in % of the sum of valproic acid plus all detected and quantified metabolites (= 100%). These percentages have proved to be more informative than the absolute quantitative data of the single metabolites. Besides the diene metabolites, the following metabolites are included: E-2-ene and Z-2-ene, cw-3-ene and trans-3-ene, 4-ene, 2-propyl-3-hydroxypentanoic acid, 2-propyl-3-oxopentanoic acid, 2-propyl-4-hydroxypentanoic acid, 2-propyl-5-hydroxypentanoic acid and 2-propylglutaric acid. It is evident that both the number and the concentration of the single diene metabolites are increased if clinical side-effects are present. Drastically enhanced amounts were found in a case with fatal hepatic failure (6) . Similar results were obtained in 4 other fatal cases, although the concentrations of the diene metabolites in plasma and urine were not so greatly elevated äs in the patient cited, and the metabolic patterns were slightly different (12) . E-2.4-diene, diene/2, and diene/3 may be regarded äs normal metabolic products, and the last one is always the most prominent doubly unsaturated metabolite. E-2-4-diene is sometimes missing, and when present, its concentration is always very low in normal patients. In contrast, the 4.4'-diene is thought to be abnormal due to its complete absence from children and adults treated without complications. Diene/4 was sporadically observed only in adults, and its enhanced formation in the presence of sideeffects and hepatotoxicity qualified this metabolite äs possibly toxic.
Discussion
So far, we have detected a total of 5 doubly unsaturated metabolites of valproic acid. There are numerous possible isomers of these diene metabolites, which cannot be reliably differentiated and characterized by mass-spectrometry. To ensure the correct assignment of the two double bond positions, we therefore synthesized a series of doubly unsaturated derivatives of valproic acid (8) . Only two of these synthetic compounds were found to be identical with native metabolites: 2(2-propenyl)-4-pentenoic acid (4.4 ; -diene) and E-2-propyl-2.4-pentadienoic acid (E-2.4-diene). The three other native diene metabolites are still non-defined with respect to the positioii and stereochemistry of the two double bonds. They are therefore termed diene/2, diene/3, and diene/4. However, their exact structures may be inferred from figure 8, and these are illustrated in the metabolic scheine in figure 9 . All possible diene derivatives containing a terminal double bond have been synthesized and the retention times of these compounds are smaller than those of the native metabolites, diene/2, diene/3 and diene/4. Some of the synthetic products containing a terminal double bond have the same retention time äs the metabolic products, i.e. 4-ene, 4.4'-diene, and E-2.4-diene. Furthermore, it may be concluded from figure  8 , that a) the two double bonds in the native diene/2, diene/3, and diene/4 metabolites are distributed in both cafbon chains, This means that one double bond must be localized in 3, 4 position of the metabolites diene/2, diene/3 and diene/4. A shift of the terrninal double bond to the inner tertiary carbon atom is accompanied by an increäse in retention time (see fig. 8 ). Therefore, the structure of diene/4 and also of diene/3 is assumed to be rather a 2.3'-diene than a 3.3'-diene; Since the 2-ene is the main metabolite of the mono-ene group, its function äs a precursor is more plausible than that of the 3-ene, normally only of minor importance. Consequently, diene/2 might be assigned a 3.3'-diene structure with the 3^ene äs precursor.
The formation of the E-2.4-diene is unusual in so far äs the second double bond is introduced into the propenylic and not into the propylic group. In this connection, it should be lioted that 2.4^pentadienoic acid is formed metabolically from 4-pentenoic acid (13) .
The metabolic pattern of valproic acid metabolism in fatal hepatic failure is characterized by an increased formation of doubly unsaturated metabolites äs exemplified in a patient (see tab. 3) (6). The 4.4'-diene is considered to be an abnormal metabolite, which is never found in patients without severe complications. Its formation seems to be always accompanied by the 4-ene, which may also be sporadically obŝ erved in normal patients (but not more than 0.05%). The toxic effects of the 4-ene are thought to be analogous to the features of Reye's syndrome induced in rats by 4-pentenoic acid (14) . As the 2-ene (main metabolite of the mono-ene group) and the 3·ê ne äs well äs the E-2.4-diene, diene/2, and diene/3 (main metabolite of the diene group) are normal and almost obligatory metabolites, the distinct appearance of the 4.4'-diene, the 4-ene, and the diene/4 in fatal hepatic damage (6, 12) may indicate a metabolite aberration, the cause of which is still unknown. The percentage distfibution of the unsaturated met abolites was not uiiique in the fatal cases. Reversible valproic acid-induced side-effects (drowsiness, CH 2 = CH lethargy, vomiting, anorexia etc.) are known, and laboratory data (moderate increase in blood ammonia and transaminases) indicate disturbed liver functions in association with a changed valproic acid metabolism. Preliminary results in such cases have demonstrated that increased urinary diene/3 might be indicative of a disturbed metabolic Situation, if its urinary concentration is above the upper limit of 3% (valproic acid plus all found metabolites = 100%) (12) . In addition, both the 4-ene and the 4.4'-diene may be detected in traces.
It is very difficult to decide When vaiproic acid therapy should be discontinued^ becäuse conventional liver function tests do not seem to predict hepatotoxicity. On rare occasions, valproic acid may initiate a type of liver failure that almost always leads to the death of the patient. The presence of side-effects associated with clinical signs of liver or pancreatic dysfunction, together with the appearance of the 4-ene, and the 4.4'-diene, and increased excretion of the diene/3 are an indication that valproic acid treatment should be discontinued. One group of patients has been identified, which is particularly at risk; these are strongly retarded children with intractable epilepsy on multiple antiepileptic drug therapy. Attention is imperative especially during the first 6 months after onset of valproic acid therapy.
